Key facts
- This page summarizes Jaren Landen's Form 4 filing for CASSAVA SCIENCES INC (SAVA).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 20 Nov 2024, 16:39.
Jaren Landen - 18 Nov 2024 Form 4 Insider Report for CASSAVA SCIENCES INC (SAVA)
- Reporting relationship
- Chief Clinical Dev. Officer
- Issuer ticker
- SAVA
- Reported as of
- 18 Nov 2024
- Net transaction value
- $0
- Reporting owner signature
- /s/ Eric J. Schoen by Power of Attorney
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Jaren Landen filed Form 4 for CASSAVA SCIENCES INC (SAVA) on 20 Nov 2024.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SAVA
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +85,000
- Change %
- Price
- $0.000000
- Shares after
- 85,000
- Date
- 18 Nov 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 85,000
- Exercise price
- $27.95
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The stock option vests in four equal annual installments (25% each year) with the initial 25% vesting on November 18, 2025.